Our mission is to develop innovative RNA-based therapeutics that specifically target viruses.
Hybridize Pharma is a pre-clinical stage biotech company that spun out from the Leiden University Medical Center in September 2019. We are a R&D-performing SME, creating value by developing RNA-based therapeutics specifically targeting viruses that become reactivated under immunosuppression. Hybridize Pharma has the ambition to become a global player in developing anti-viral therapies.
The concept of Hybridize Pharma was founded in July 2018 by Eric van der Veer, Anton Jan van Zonneveld and Jurriën Prins.
Antisense oligonucleotide picture of the kidney
Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.